Practical realization of guidelines for treatment of type 2 diabetes with a high cardiovascular risk

In recent years, GLP-1 receptor-agonists and SGLT2 inhibitors have shown a very high level of evidence and recommendation for the treatment of patients with type-2-diabetes and high cardiovascular risk. These medications were developed for the treatment of hyperglycemia, cardiovascular endpoint studies showed a CV-benefit independent of baseline-HbA1c. In the practical im-plementation of these therapies, however, there are ongoing challenges that need to be identified and overcome - especially for this well described high risk population. J Kardiol 2023; 30 (5-6): 119-22.